248 related articles for article (PubMed ID: 32800532)
1. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
[TBL] [Abstract][Full Text] [Related]
2. An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Variables of Edaravone in Subjects with Mild, Moderate, or No Renal Impairment.
Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Kondo K
Clin Ther; 2020 Sep; 42(9):1699-1714. PubMed ID: 32868037
[TBL] [Abstract][Full Text] [Related]
3. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
Urva S; Quinlan T; Landry J; Ma X; Martin JA; Benson CT
Clin Pharmacokinet; 2022 Jul; 61(7):1057-1067. PubMed ID: 35674880
[TBL] [Abstract][Full Text] [Related]
4. The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor.
Kielbasa W; Tesfaye E; Luffer-Atlas D; Mitchell MI; Turik MA
Eur J Clin Pharmacol; 2013 Dec; 69(12):2011-9. PubMed ID: 23955175
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
[TBL] [Abstract][Full Text] [Related]
7. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.
Peveling-Oberhag J; Zeuzem S; Yong WP; Kunz T; Paquet T; Bouillaud E; Urva S; Anak O; Sellami D; Kobalava Z
Clin Ther; 2013 Mar; 35(3):215-25. PubMed ID: 23453404
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.
Tomkinson H; Kemp J; Oliver S; Swaisland H; Taboada M; Morris T
BMC Clin Pharmacol; 2011 Mar; 11():3. PubMed ID: 21414193
[TBL] [Abstract][Full Text] [Related]
9. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
10. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment.
Grasela DM; Christofalo B; Kollia GD; Duncan G; Noveck R; Manning JA; LaCreta FP
Pharmacotherapy; 2000 Jun; 20(6 Pt 2):87S-94S. PubMed ID: 10850525
[TBL] [Abstract][Full Text] [Related]
11. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment.
Sahasrabudhe V; Terra SG; Hickman A; Saur D; Raje S; Shi H; Matschke K; Zhou S; Cutler DL
Clin Ther; 2018 Oct; 40(10):1701-1710. PubMed ID: 30224193
[TBL] [Abstract][Full Text] [Related]
13. Asenapine pharmacokinetics in hepatic and renal impairment.
Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
[TBL] [Abstract][Full Text] [Related]
15. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
Zhao Q; Iyer GR; Verhaeghe T; Truyen L
J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
Schnell D; Buschke S; Fuchs H; Gansser D; Goeldner RG; Uttenreuther-Fischer M; Stopfer P; Wind S; Petersen-Sylla M; Halabi A; Koenen R
Cancer Chemother Pharmacol; 2014 Aug; 74(2):267-75. PubMed ID: 24906422
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment.
Kaufmann P; Cruz HG; Krause A; Ulč I; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2016 Aug; 82(2):369-79. PubMed ID: 27062188
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
[TBL] [Abstract][Full Text] [Related]
20. A Randomized, Single-Blind, Placebo-Controlled, 3-Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects.
Shimizu H; Inoue S; Endo M; Nakamaru Y; Yoshida K; Natori T; Kakubari M; Akimoto M; Kondo K
Clin Pharmacol Drug Dev; 2021 Jan; 10(1):46-56. PubMed ID: 32543120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
